PDUFA VIII Keeps Every Review Clock and Hires Four Auditors
Industry renegotiated what it pays FDA without changing what it gets. The clocks held. What expanded is the apparatus for verifying the money buys reviewers.
By subject
Four Health Systems Automated the Prior Authorization Question, Not the Answer
The piece of the federal prior authorization mandate that shipped five months early is the piece that cannot deny anything.
Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It
Health Canada cleared Vanrafia on a Week 36 proteinuria readout. Novartis will not take that same package into Canadian pricing review.
CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route
QuickAccess read/Oncology/Antibody CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route Athithi Verma· 19 August 2026· 2 min read· Synopulse The 60-day comment period on CMS-4215-P closed at 5pm on 17 August 2026. The proposed rule, published in the Federal Register on 16 June 2026, would codify … Read more
Payers Do Not Cover Wellness. In Women’s Health, That Is a Naming Decision.
The sharpest advice in the roadmap is about vocabulary. Payers will not fund wellness, and in women’s health that classification is partly a choice.
The FDA Approved a Device and a Sentence. The Sentence Is About Other Molecules.
The label credits outcomes trials run on statins and monoclonal antibody PCSK9 inhibitors. LEROCHOL is neither, and has no outcomes trial of its own.
One Missed, One Published the Arm That Failed, One Disclosed a Verb
Three Phase 3 toplines in one day, and the detail released runs inversely to the strength of the result. One company disclosed no number at all.
Two TROP2 Conjugates Reached the Same Patients Ten Weeks Apart, and Payers Finally Have a Choice to Make
Until this summer every approved ADC held its indication alone. Two TROP2 conjugates now share one first-line population, and payers finally have a comparator.
CMS Projects: Fewer Losses and Bigger Savings. That Only Works If the Sick Are Removed.
CMS forecasts fewer disenrollments than CBO and higher savings. Both hold only if the people removed are the expensive ones, which means the sick.
Two Dominican High-Cost Lists Overlap by Only 44 Products. FOMAC Would Be a Third.
The country already covers this. Two schemes list 120 and 115 high-cost medicines, overlapping by 44. FOMAC would be a third list, starting at 13.